CYTOSORBENTS CORPORATION Net Cash Provided by (Used in) Investing Activities, Continuing Operations
CYTOSORBENTS CORPORATION (CTSO) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$556.99 thousand for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-07
- CYTOSORBENTS CORPORATION net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$352.53K, a 117.30% decline year-over-year.
- CYTOSORBENTS CORPORATION net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$204.46K.
- CYTOSORBENTS CORPORATION net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$98.17K.
- CYTOSORBENTS CORPORATION net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $62.38K, a 94.11% decline year-over-year.
- CYTOSORBENTS CORPORATION net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $1.60M.
- CYTOSORBENTS CORPORATION net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$890.90K.
- CYTOSORBENTS CORPORATION net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$2.31M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$352.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$556.99K 10-Q · filed 2017-08-07 | -$655.15K derived: sum of 3 quarters · filed 2017-08-07 | -$592.78K derived: sum of 4 quarters · filed 2017-08-07 |
| 2017-03-31 | -$204.46K 10-Q · filed 2017-05-08 | -$302.63K derived: sum of 2 quarters · filed 2017-05-08 | -$240.25K derived: sum of 3 quarters · filed 2017-05-08 | $1.80M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-12-31 | -$98.17K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$35.79K derived: sum of 2 quarters · filed 2017-03-03 | $2.00M derived: sum of 3 quarters · filed 2017-08-07 | $1.60M 10-K · filed 2017-03-03 |
| 2016-09-30 | $62.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $2.10M derived: sum of 2 quarters · filed 2017-08-07 | $1.69M 10-Q · filed 2016-11-07 | $1.23M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $1.63M 10-Q · filed 2017-08-07 | $1.16M derived: sum of 3 quarters · filed 2017-08-07 | $2.22M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-03-31 | -$404.92K 10-Q · filed 2017-05-08 | -$873.16K derived: sum of 2 quarters · filed 2017-05-08 | $185.59K derived: sum of 3 quarters · filed 2017-05-08 | -$161.19K derived: sum of 4 quarters · filed 2017-05-08 |
| 2015-12-31 | -$468.24K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | $590.51K derived: sum of 2 quarters · filed 2017-03-03 | $243.72K derived: sum of 3 quarters · filed 2017-03-03 | -$890.90K 10-K · filed 2017-03-03 |
| 2015-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $711.96K derived: sum of 2 quarters · filed 2016-11-07 | -$422.66K 10-Q · filed 2016-11-07 | $4.79M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-06-30 | -$346.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$1.48M 10-Q · filed 2016-08-09 | $3.73M derived: sum of 3 quarters · filed 2017-03-03 | |
| 2015-03-31 | -$1.13M 10-Q · filed 2016-05-09 | $4.08M derived: sum of 2 quarters · filed 2017-03-03 | ||
| 2014-12-31 | $5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$2.31M 10-K · filed 2017-03-03 | ||
| 2014-09-30 | -$7.53M 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |